Skip to search formSkip to main contentSkip to account menu

1 ML certolizumab pegol 200 MG/ML Prefilled Syringe [Cimzia]

Known as: CERTOLIZUMAB PEGOL 200 mg in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [Cimzia], Cimzia 200 MG in 1 ML Prefilled Syringe, Cimzia 200 MG per 1 ML Prefilled Syringe 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Certolizumab pegol (Cimzia ® ) is a PEGylated, Fab′-only, recombinant humanized antibody against TNF-α. Subcutaneous certolizumab… 
2018
2018
Tumor necrosis factor α (TNFα) drives the pathophysiology of human autoimmune diseases and consequently, neutralizing antibodies… 
Review
2018
Review
2018
The binding of the tumor necrosis factor α (TNFα) to its cognate receptor initiates many immune and inflammatory processes. The… 
Review
2017
Review
2017
BACKGROUND Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic… 
2017
2017
Certolizumab pegol (Cimzia®), a tumour necrosis factor-α (TNF) antagonist, is an effective and well-tolerated option for the… 
Review
2014
Review
2014
Certolizumab pegol (Cimzia®) is a polyethylene glycolylated antigen-binding fragment of a recombinant human monoclonal antibody… 
2013
2013
Antibodies are currently the fastest growing class of therapeutic proteins. When antibody fragments are included, there are over… 
Review
2013
Review
2013
Certolizumab pegol (Cimzia®) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal… 
Review
2013
Review
2013
Rheumatoid arthritis (RA) is an autoimmune chronic disease which is associated with an increasing disability in patients and high…